Drug Trial Radar · NCT07811037
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
332
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Beijing Sungen Biomedical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/IIa clinical study SGT003 in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
SGT003Drug
Dosage Form: Injection Strength: 50 mg (5 mL) per vial Dosage and Administration: Subjects will receive SGT003 (investigational product) via intravenous (IV) infusion on Day 1 (D1) of each cycle. Dose: During the Phase I dose-escalation, subjects will be dosed according to the assigned dose cohort; during the Phase IIa dose-expansion stage, subjects will be dosed according to the selected expansion dose. Duration of Administration: For each subject, the first infusion will be completed within 90 minutes. If no infusion-related reaction (IRR) and/or hypersensitivity reaction occurs, the subsequent infusion duration may be shortened to no less than 60 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs), immune-related Adverse Events (irAEs)Time frame: First dose up to 28 days (+3 days) after EOT, or prior to initiation of other anti-tumor therapy, whichever occurs first.
- Phase I: Dose Limit Toxicity (DLTs)Time frame: Within the first dose cycle (Day1-Day21) of SGT003
- Phase I: Maximum Toxicity Dose(MTD)Time frame: Within the first dose cycle (Day1-Day21) of SGT003
- Phase I: Recommended Phase II dose (RP2D)Time frame: Within the first dose cycle (Day1-Day21) of SGT003
- Phase IIa: Objective Response Rate (ORR)Time frame: from date of randomization, until disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent, death, loss to follow-up, or study termination, whichever occurs first. average Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.